Thousand Oaks Biopharmaceuticals secures series A financing of CNY 300 million

On January 1, 2019, at the beginning of the new year, Thousand Oaks Biopharmaceuticals Co., LTD, located in the Hi-park in Haimen, Nantong, Jiangsu Province, officially announced the completion of its series A financing of CNY 300 million led by New Alliance Capital and followed by Addor Capital, TenYall & Sumin, Beyond Fund, Qianrong Capital, Jilin Aodong Pharma and Blue Bay Capital. Blue Bay Capital as an investor in the angel round now made an additional investment. New Alliance Capital, Addor Capital and TenYall & Sumin were newly admitted into the Board of Directors of Thousand Oaks Biopharmaceuticals. The financing was the largest one recently completed in the biopharmaceutical CDMO and cell culture media industry.

Thousand Oaks Biopharmaceuticals is a biopharmaceutical company focusing on CMC bio-manufacturing. It assists customers in providing high-end biopharmaceuticals that are effective and affordable to common people around the world, and firmly guarding the development of the bio-pharmaceutical industry. Thousand Oaks Biopharmaceuticals has developed an industrial layout integrating raw materials, consumables, pharmaceutical equipment, technical services and contract production. It provides customers with one-stop services ranging from gene fragments to drugs to be marketed, including cell line development, cell culture media optimization, cell culture media process development, purification process development, pharmaceutical process development and stability inspection, testing and analysis method development and verification, test outsourcing service, pilot and commercial scale (GMP level) production, as well as the production, registration and application of pre-clinical and clinical research samples and post-market products. The series A financing was an important milestone in Thousand Oaks Biopharmaceuticals’ development history. The funds raised will be used to ramp up its CDMO capacity.

Moreover, JSBioscienses also announced today its Cell Culture Media Plant Phase II, located in the Hi-park in Nantong, Jiangsu as well, had been started for construction. The plant adopts the latest design concept and fully complies with the international GMP requirements. It is expected to be completed and put into operation in the second half of 2019, and will become the world's largest dry powder cell culture media production base once it’s completed.

Thousand Oaks Biopharmaceuticals Co., Ltd., founded by Dr. Shun Luo, is led by a team of capable, experienced and highly international executives, including those from BMS, Singapore A-Bio, Amgen, Merck and Genentech. Its CDMO plant in Haimen was constructed and put into operation within one year, and has so far contracted production amounting up to tens of millions yuan. After more than one year of operation under the Chinese and American GMP standards, it has assisted customers to successfully complete the GMP batch production of several samples in the clinical stage, and therefore become a loyal partner of many leading biopharmaceutical companies in China. JSBiosciences, a subsidiary of Thousand Oaks Biopharmaceuticals, was founded in Lanzhou in 2011. It is engaged in the research and development and production of serum-free cell culture media, and is committed to ending the long-term monopoly of imported cell culture media manufacturers. At present, it provides many large vaccine and pharmaceutical companies with cell culture media products and services for long, and keeps leading the forefront of Chinese brands. In addition, in order to further strengthen its cost control, Thousand Oaks Biopharmaceuticals worked closely with Zhejiang JYSS by independent innovation and technology research and development, to carry on forward planning of high-value consumables and single-use bioreactors required for cell culture media, which could be widely used in the preparation and production of monoclonal antibodies, recombinant protein drugs, gene therapy products, and vaccines for human, poultries and animals.

“Today, the biopharmaceutical market has undergone drastic changes. Market dominance by some brands is gone with the time,” said Dr. Shun Luo, Chairman and President of Thousand Oaks Biopharmaceuticals. “The company has significantly improved the production efficiency of biopharmaceuticals by its independent innovation and disruptive production processes and technologies, introduced international standards to enforce its integrated layout on biopharmaceutical raw materials, equipment, and processing, to therefore help customers accelerate drug development and marketing progress, ensure international standard-compliant product quality, improve production efficiency, reduce production costs, and thus remain invincible in the fierce market competition. As a result, we’ll be able to achieve supply of high-end effective and affordable biopharmaceuticals to common people all over the world!”